Methods
Results -Stent deployment was successful in all patients. Significant improvements were observed one day after placement compared with before placement, with no change at 30 and 90 days, in dyspnoea index (mean (SD) 3 .2 (0.7) before stent insertion compared with 1.8 (0.7) one day after insertion); Karnofsky index (32 (18) before insertion compared with 55 (15) one day after insertion); and obstruction of airway diameter (85 (11)% before insertion compared with 10 (12)% on day 1 after stent insertion). Stent-related complications needing later interventions included retained secretions (five patients), granuloma formation at ends of the stent (four patients), and stent migration (four patients). Over a median observation period of two months (range two days to 8. 5 
Methods

PATIENTS
Twenty seven patients (20 men) of mean age 60 years (range 41-78) were treated with one or more Wallstents. They all presented with inoperable malignant lesions of the central airways. The diagnoses were 21 bronchogenic carcinoma, three oesophageal carcinoma, two thyroid carcinoma, and one lymphoma. After endoscopic treatment (Nd:YAG laser resection and/or dilatation) with the rigid bronchoscope under general anaesthesia, 24 patients exhibited residual obstruction of >50% of the airway and three patients suffered from malignant fistulae without stenosis (one tracheooesophageal, one left broncho-oesophageal, and one bronchopleural stump fistula after right pneumonectomy).
STENT SPECIFICATIONS AND INSERTION TECHNIQUE
The Airway Wallstent is a self-expandable stent made of woven stainless steel filaments. The unconstrained stent dimensions designed for the airways were: diameters 12, 14, 16, and 18 mm; lengths: 25, 30, 35, 45, and 60 mm. is mounted in a compressed and elongated shape ( fig 2) 
EFFICACY OF PALLIATION AND STENT-RELATED COMPLICATIONS
A comparison of the dyspnoea scores, Karnofsky scale, and obstruction of the airway diameter before and after stent insertion showed significant and lasting improvements (p<0.01) (fig 3) . For Over the three month study period the following stent-related complications occurred which were diagnosed and dealt with at unplanned visits in 10 patients before day 30 and in five after day 30: retained secretions within the stent necessitating bronchoscopic as-piration (five), granuloma formation at the end of the stents necessitating careful laser resection, radiotherapy or additional stent placement (four), stent migration necessitating endoscopic stent removal (six). Two of the six migrations occurred after full dose external beam radiation with widening of the stented airway diameter beyond the unconstrained stent diameter. They had been expected and stent removal planned, so only four migrations were counted as complications related to the stent itself. The chest radiographs were helpful in detecting stent migration. In all patients the stent covering remained intact without delamination or tumour ingrowth during the follow up period of three months.
Discussion
The results of our study confirm the usefulness of the new covered Airway Wallstent for the relief of obstructions and sealing of fistulae in malignancies of the central airways. The polyurethane covering successfully prevented reobstruction of the area covered by the stent and, with a maximal follow up of 8.5 months, no deterioration of the covering or delamination was observed.
The insertion of the stents with the flexible or the rigid delivery device proved to be relatively simple. One caveat must be mentioned, however. The considerable shortening of the Wallstent, which is more pronounced when using the Telestep delivery device, makes the choice of adequate dimensions of the stent more difficult than with stents that do not shorten on placement. This problem is, however, overcome with increasing experience with the device.
Symptom relief was excellent and lasting, and comparable to the results obtained with silicone stents. 1-3 The advantage of the Airway Wallstent over cylindrical silicone stents is its feasibility in narrow (diameter < 10 mm after dilatation) or conical stenoses or in stenotic airways with greatly varying diameters. It was particularly useful in the three patients with malignant fistulae. The optimal solution in these patients, in whom the disease is usually advanced and who therefore have a short life expectancy, is the sealing of the fistula through a tightly fitting stent. In our experience the available silicone stents, such as the Dumon or the dynamic Y stent,7 do not seal off fistulae in airways with normal diameters.
The Airway Wallstent had similar complications to those of silicone stents. The major difference was the retention of secretions which necessitated bronchoscopy in five (19%) of the 27 patients. This propensity is probably due to the covering being on the outside of the stent with the wire mesh inside being a lot less smooth than a silicone surface.
The addition, of radiotherapy might well have enhanced the palliative effect of stent placement and, in our experience, represents an ideal therapeutic complement.2
In conclusion we found that the new Airway Wallstent is well suited for stenting of narrow airways or stenotic segments with varying diameters, and for sealing malignant fistulae in airways without concomitant stenosis. However, granuloma formation at the stent ends and retention of secretions within the stent remain problems which may be helped if the wire ends were blunted and the inside of the stent covered in order to smooth the inner surface.
